NASDAQ:BLCM

Bellicum Pharmaceuticals Stock Forecast, Price & News

$2.95
-0.10 (-3.28 %)
(As of 07/29/2021 12:36 PM ET)
Add
Compare
Today's Range
$2.95
$2.97
50-Day Range
$2.64
$3.66
52-Week Range
$2.57
$8.19
Volume400 shs
Average Volume413,184 shs
Market Capitalization$24.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
30 days | 90 days | 365 days | Advanced Chart
Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

981st out of 2,214 stocks

Pharmaceutical Preparations Industry

472nd out of 869 stocks

Analyst Opinion: 3.0Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

Is Bellicum Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Bellicum Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View analyst ratings for Bellicum Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Bellicum Pharmaceuticals?

Wall Street analysts have given Bellicum Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bellicum Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Bellicum Pharmaceuticals
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Monday, May, 17th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.37) by $0.29.
View Bellicum Pharmaceuticals' earnings history
.

How has Bellicum Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BLCM shares have decreased by 59.5% and is now trading at $2.95.
View which stocks have been most impacted by COVID-19
.

When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?

Bellicum Pharmaceuticals shares reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BLCM?

2 analysts have issued 12-month price objectives for Bellicum Pharmaceuticals' shares. Their forecasts range from $4.50 to $4.50. On average, they anticipate Bellicum Pharmaceuticals' stock price to reach $4.50 in the next year. This suggests a possible upside of 52.5% from the stock's current price.
View analysts' price targets for Bellicum Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the following people:
  • Richard A. Fair, President, Chief Executive Officer & Director
  • Aaron Foster, Senior Vice President & Head-Research
  • Joseph Howard Senesac, Vice President-Viral Vector Development

Who are some of Bellicum Pharmaceuticals' key competitors?

What other stocks do shareholders of Bellicum Pharmaceuticals own?

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $2.95.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals has a market capitalization of $24.77 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-7,720,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis.

How many employees does Bellicum Pharmaceuticals have?

Bellicum Pharmaceuticals employs 10 workers across the globe.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is www.bellicum.com.

Where are Bellicum Pharmaceuticals' headquarters?

Bellicum Pharmaceuticals is headquartered at 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.